Technical Analysis for CELU - Celularity Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 3.19 | 1.92% | 0.06 |
CELU closed up 1.92 percent on Monday, July 1, 2024, on 59 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | 1.92% | |
| Bullish Engulfing | Bullish | 1.92% | |
| Stochastic Buy Signal | Bullish | 1.92% | |
| Bollinger Band Squeeze | Range Contraction | 1.92% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 10 hours ago |
| 10 DMA Support | about 10 hours ago |
| 50 DMA Support | about 10 hours ago |
| 200 DMA Support | about 10 hours ago |
| 2x Volume Pace | about 10 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/12/2024
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Cancer Biology Immune System Stem Cell Cell Therapy Natural Killer Cell Lymphocytes Therapeutic Solutions
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Cancer Biology Immune System Stem Cell Cell Therapy Natural Killer Cell Lymphocytes Therapeutic Solutions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.97 |
| 52 Week Low | 1.59 |
| Average Volume | 30,776 |
| 200-Day Moving Average | 3.20 |
| 50-Day Moving Average | 3.14 |
| 20-Day Moving Average | 3.13 |
| 10-Day Moving Average | 3.04 |
| Average True Range | 0.29 |
| RSI (14) | 51.46 |
| ADX | 17.9 |
| +DI | 19.04 |
| -DI | 17.03 |
| Chandelier Exit (Long, 3 ATRs) | 2.78 |
| Chandelier Exit (Short, 3 ATRs) | 3.51 |
| Upper Bollinger Bands | 3.39 |
| Lower Bollinger Band | 2.88 |
| Percent B (%b) | 0.61 |
| BandWidth | 16.29 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0087 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.70 | ||||
| Resistance 3 (R3) | 3.69 | 3.52 | 3.62 | ||
| Resistance 2 (R2) | 3.52 | 3.39 | 3.52 | 3.59 | |
| Resistance 1 (R1) | 3.35 | 3.31 | 3.27 | 3.36 | 3.56 |
| Pivot Point | 3.18 | 3.18 | 3.13 | 3.18 | 3.18 |
| Support 1 (S1) | 3.01 | 3.05 | 2.93 | 3.02 | 2.82 |
| Support 2 (S2) | 2.84 | 2.97 | 2.84 | 2.79 | |
| Support 3 (S3) | 2.67 | 2.84 | 2.77 | ||
| Support 4 (S4) | 2.68 |
